This recombinant monoclonal antibody is developed as a research-grade biosimilar to Enoblizumab, targeting CD276 (B7-H3), a member of the B7 family of immune checkpoint proteins. CD276 is a type I transmembrane glycoprotein that functions as an immunoregulatory molecule, modulating T-cell activation and immune responses. While its precise immunological role remains complex, CD276 is widely overexpressed across multiple solid tumors including non-small cell lung cancer, renal cell carcinoma, prostate cancer, and various other malignancies, where it correlates with poor prognosis and promotes tumor immune evasion. Its restricted expression in normal tissues makes it an attractive target for cancer immunotherapy research.
Enoblizumab is a humanized IgG1 monoclonal antibody designed to bind CD276 and has been investigated in clinical trials for advanced solid tumors. This biosimilar antibody serves as a valuable research tool for investigating CD276-mediated immune regulation, exploring tumor microenvironment interactions, and evaluating potential therapeutic strategies targeting this immune checkpoint molecule. It enables researchers to study CD276 biology and its role in cancer progression and immune suppression.
Email: support@cusabio.com
Distributors Worldwide